Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 1
2011 2
2012 8
2013 5
2014 11
2015 10
2016 7
2017 7
2018 21
2019 10
2020 20
2021 8
2022 9
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Breast cancer screening: a dividing controversy.
Khrouf S, Letaief Ksontini F, Ayadi M, Belhaj Ali Rais H, Mezlini A. Khrouf S, et al. Among authors: mezlini a. Tunis Med. 2020 Jan;98(1):22-34. Tunis Med. 2020. PMID: 32395774 Review.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.
Jlassi A, Manai M, Morjen M, Sahraoui G, Elasmi Allal M, ELBini-Dhouib I, Naija L, Charfi L, Rejaibi R, Ben Ahmed M, Marrakchi N, Srairi-Abid N, Mezlini A, Manai M, Mrad K, Doghri R. Jlassi A, et al. Among authors: mezlini a. PLoS One. 2023 Mar 23;18(3):e0278849. doi: 10.1371/journal.pone.0278849. eCollection 2023. PLoS One. 2023. PMID: 36952478 Free PMC article.
Larynx preservation: what is the best non-surgical strategy?
Lagha A, Chraiet N, Labidi S, Rifi H, Ayadi M, Krimi S, Allani B, Raies H, Touati S, Boussen H, Kochbati L, Mezlini A. Lagha A, et al. Among authors: mezlini a. Crit Rev Oncol Hematol. 2013 Nov;88(2):447-58. doi: 10.1016/j.critrevonc.2013.05.005. Epub 2013 Jun 5. Crit Rev Oncol Hematol. 2013. PMID: 23755889 Review.
Target therapy for metastatic breast cancer.
Rachdi H, Mokrani A, Batti R, Ayadi M, Chraiet N, Mezlini A. Rachdi H, et al. Among authors: mezlini a. Tunis Med. 2018 Aug-Sep;96(8-9):465-471. Tunis Med. 2018. PMID: 30430522
113 results